CN1193789C - 甲状腺素在治疗肿瘤中的应用 - Google Patents
甲状腺素在治疗肿瘤中的应用 Download PDFInfo
- Publication number
- CN1193789C CN1193789C CNB991187660A CN99118766A CN1193789C CN 1193789 C CN1193789 C CN 1193789C CN B991187660 A CNB991187660 A CN B991187660A CN 99118766 A CN99118766 A CN 99118766A CN 1193789 C CN1193789 C CN 1193789C
- Authority
- CN
- China
- Prior art keywords
- thyroxine
- tumor
- application
- quick
- treating tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及甲状腺素在治疗肿瘤中的应用。它具有抢夺肿瘤细胞能源代谢原料，促进细胞器恢复和恢复细胞正常代谢途径的功能。用甲状腺素治疗肿瘤无毒副作用，症状改善快，肿瘤逆转过程快，治愈彻底。
Description
本发明涉及甲状腺素的用途。
甲状腺素的主要作用为维持正常生长发育，促进代谢和增加产热，提高交感—肾上腺系统的感受性。临床上主要应用于甲状腺功能低下、呆小病、粘液性水肿、甲亢的治疗。
本发明的目的在于提供甲状腺素在治疗肿瘤中的应用。
为了更好的理解本发明的实质，下面将甲状腺素治疗肿瘤的基理进行说明。
恶性肿瘤细胞有以下共同点：瘤细胞内的细胞器包括线粒体、内浆网及高尔基体不发达；肿瘤细胞组织即使在氧气供应充足的条件下，也都是以无氧酵解获取能量，说明肿瘤细胞有自己一套能量代谢新途径。这种新机制由于没有机体存在的负反馈调节作用，因此使瘤细胞的代谢异常活跃无限制；肿瘤细胞内细胞色素氧化酶和琥珀酸脱氢酶均减少，也能说明细胞原来的能量代谢途径改变了；瘤细胞内其它酶的改变与正常组织比较，只是含量的改变或活性的改变，并非质的改变。上述几个方面均说明肿瘤细胞与正常组织的区别本质就是能量代谢途径的改变。
使用甲状腺素可以抢夺肿瘤细胞能源代谢原料，促进细胞器恢复，恢复细胞正常代谢途径。
本发明的优点在于用甲状腺素治疗肿瘤无毒副作用，患者症状改善快，肿瘤逆转过程快，治愈彻底。
下面将描述本发明的实施例，但本发明的内容完全不局限于此。
实施例1：治疗胃腺癌，口服甲状腺素40mg，每日2次，连续应用80天。静脉滴注辅酶A100μ×8+三磷酸腺苷二钠20mg×8+细胞色素C15mg×4+10％氯化钾10ml×1+0.9％氯化钠500ml，每日一次连续使用70天。肌肉注射，复方黄连素2ml×2+庆大霉素4000μ×2+阿托品0.5×1，每日一次，连续肌肉注射20天。氟哌酸胶囊2粒，每日3次，连续服用70天。连续用药80天停药后胃部肿物完全消失，肿瘤组织逆转为增生组织。
Claims (1)
1、一种甲状腺素在制备治疗胃腺癌的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB991187660A CN1193789C (zh) | 1999-09-10 | 1999-09-10 | 甲状腺素在治疗肿瘤中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB991187660A CN1193789C (zh) | 1999-09-10 | 1999-09-10 | 甲状腺素在治疗肿瘤中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1287860A CN1287860A (zh) | 2001-03-21 |
| CN1193789C true CN1193789C (zh) | 2005-03-23 |
Family
ID=5280535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB991187660A Expired - Fee Related CN1193789C (zh) | 1999-09-10 | 1999-09-10 | 甲状腺素在治疗肿瘤中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1193789C (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7345068B2 (en) * | 2002-02-07 | 2008-03-18 | Hitoshi Endou | Aromatic amino acid derivatives and medicinal compositions |
-
1999
- 1999-09-10 CN CNB991187660A patent/CN1193789C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1287860A (zh) | 2001-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiao et al. | Nanoparticle‐embedded electrospun fiber–covered stent to assist intraluminal photodynamic treatment of oesophageal cancer | |
| CN107670044A (zh) | 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法 | |
| CN105288622B (zh) | 同时负载化疗药物和光动力治疗药物的细胞膜微囊的制备方法 | |
| SG146666A1 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
| HRP20080598T3 (en) | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer | |
| RU2013110491A (ru) | Использование кислой лизосомной липазы для лечения дефицита кислой лизосомной липазы у больных | |
| AU691617B2 (en) | Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases | |
| US5902825A (en) | Composition and method for the palliation of pain associated with diseases of the bone and bone joints | |
| CN1193789C (zh) | 甲状腺素在治疗肿瘤中的应用 | |
| Yamaoka et al. | Confirmation of efficacy, elucidation of mechanism, and new search for indications of radon therapy | |
| CN108144074A (zh) | 一种放射性碘标记的黑色素纳米颗粒、水凝胶及制法、应用 | |
| CN114230610B (zh) | 放射性标记物、其前体化合物、及制法和应用 | |
| Pryme et al. | Dietary phytohaemagglutinin slows down the proliferation of a mouse plasmacytoma (MPC-11) tumour in Balb/c mice | |
| IL159770A0 (en) | Calcium salts with cytotoxic activity | |
| CN102198271A (zh) | 以脂溶性光敏剂为骨架的药物-纳米磷酸钙复合体系的制备方法及其在制备光动力疗法药物中的应用 | |
| CN113209046B (zh) | 一种CoSe@BSA纳米粒子药物组合物及其制备方法和应用 | |
| WO2018148930A1 (zh) | Nadh或者fadh2在癌症病人的营养干预上的应用 | |
| CN101156911B (zh) | 一种治疗风湿、类风湿性关节炎的中药酒 | |
| CA1319107C (en) | Formulations for inhibiting glucose transport | |
| CN112604007A (zh) | 一种兼具显像与治疗转移性骨肿瘤的药物及其制法和应用 | |
| CN115177750A (zh) | 共轭聚合物用于制备甲状腺疾病放射性治疗药物的应用 | |
| Kuykendall III et al. | Radioprotectant Activity of 5‐Diethylsulfonamoylsalicylatocopper (II) in Gamma Irradiated Mice | |
| CN101204486A (zh) | 治疗肿瘤的膏药 | |
| CN117717600A (zh) | 一种促进植物乳杆菌在肿瘤中生长的增殖剂 | |
| Rojas et al. | Time dependence of interaction of misonidazole and WR-2721 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1081843 Country of ref document: HK |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |